CN109965166A - A kind of production method of lentinan drink - Google Patents
A kind of production method of lentinan drink Download PDFInfo
- Publication number
- CN109965166A CN109965166A CN201910293617.XA CN201910293617A CN109965166A CN 109965166 A CN109965166 A CN 109965166A CN 201910293617 A CN201910293617 A CN 201910293617A CN 109965166 A CN109965166 A CN 109965166A
- Authority
- CN
- China
- Prior art keywords
- grams
- lentinan
- parts
- rejuvenation
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001491 Lentinan Polymers 0.000 title claims abstract description 69
- 229940115286 lentinan Drugs 0.000 title claims abstract description 68
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 31
- 239000001963 growth medium Substances 0.000 claims abstract description 46
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 45
- 230000003716 rejuvenation Effects 0.000 claims abstract description 37
- 239000002609 medium Substances 0.000 claims abstract description 34
- 239000012530 fluid Substances 0.000 claims abstract description 28
- 235000015097 nutrients Nutrition 0.000 claims abstract description 28
- 230000003321 amplification Effects 0.000 claims abstract description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 19
- 238000001914 filtration Methods 0.000 claims abstract description 17
- 230000001580 bacterial effect Effects 0.000 claims abstract description 12
- 238000009630 liquid culture Methods 0.000 claims abstract description 8
- 239000000686 essence Substances 0.000 claims abstract description 5
- 239000002054 inoculum Substances 0.000 claims abstract description 5
- 239000012531 culture fluid Substances 0.000 claims abstract description 4
- 235000015099 wheat brans Nutrition 0.000 claims description 37
- 235000007164 Oryza sativa Nutrition 0.000 claims description 32
- 235000009566 rice Nutrition 0.000 claims description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 28
- 235000013312 flour Nutrition 0.000 claims description 24
- 240000008042 Zea mays Species 0.000 claims description 19
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 19
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 18
- 235000005822 corn Nutrition 0.000 claims description 18
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 17
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 17
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 15
- 239000005720 sucrose Substances 0.000 claims description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 14
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 229920001817 Agar Polymers 0.000 claims description 11
- 239000008272 agar Substances 0.000 claims description 11
- 229940041514 candida albicans extract Drugs 0.000 claims description 11
- 239000012138 yeast extract Substances 0.000 claims description 11
- 241000209140 Triticum Species 0.000 claims description 10
- 235000021307 Triticum Nutrition 0.000 claims description 10
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 8
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 8
- 244000062793 Sorghum vulgare Species 0.000 claims description 8
- 235000019713 millet Nutrition 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000012364 cultivation method Methods 0.000 claims description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 4
- 240000000111 Saccharum officinarum Species 0.000 claims 1
- 235000007201 Saccharum officinarum Nutrition 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 40
- 239000000203 mixture Substances 0.000 abstract description 6
- 241000209094 Oryza Species 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 23
- 150000004676 glycans Chemical class 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 235000013361 beverage Nutrition 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 241000264279 Sargassum fusiforme Species 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 240000000599 Lentinula edodes Species 0.000 description 4
- 244000061456 Solanum tuberosum Species 0.000 description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000007686 potassium Nutrition 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000004053 quinones Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BZUNJUAMQZRJIP-UHFFFAOYSA-N CPDA Natural products OCCCCCCCCCCCCCCC(O)=O BZUNJUAMQZRJIP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YUGCAAVRZWBXEQ-UHFFFAOYSA-N Precholecalciferol Natural products C=1CCC2(C)C(C(C)CCCC(C)C)CCC2C=1C=CC1=C(C)CCC(O)C1 YUGCAAVRZWBXEQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000002921 fermentation waste Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- PUGBZUWUTZUUCP-ZRKHGVCBSA-N fungisterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 PUGBZUWUTZUUCP-ZRKHGVCBSA-N 0.000 description 1
- UHQOYWRQNBWEAM-NBPRQAIYSA-N fungisterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@@H]1CC[C@@H]2C3=C(CC[C@]12C)[C@@]4(C)CC[C@@H](O)C[C@H]4C=C3 UHQOYWRQNBWEAM-NBPRQAIYSA-N 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- SWHAQEYMVUEVNF-UHFFFAOYSA-N magnesium potassium Chemical compound [Mg].[K] SWHAQEYMVUEVNF-UHFFFAOYSA-N 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- GISJHCLTIVIGLX-UHFFFAOYSA-N n-[4-[(4-chlorophenyl)methoxy]pyridin-2-yl]-2-(2,6-difluorophenyl)acetamide Chemical compound FC1=CC=CC(F)=C1CC(=O)NC1=CC(OCC=2C=CC(Cl)=CC=2)=CC=N1 GISJHCLTIVIGLX-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of production method of lentinan drink, mushroom strain, which is successively seeded in different types of rejuvenation culture medium, cultivates rejuvenation, cultivates 18~22 days in each type of rejuvenation culture medium；The strain to grow fine is accessed in fluid nutrient medium, carries out multistage amplification cultivation, every level-one 23~27 DEG C shake culture 5~7 days, every grade of inoculum concentration 10%~30%；The bacterial culture fluid that multistage amplification cultivation obtains keeps the temperature 1.5~2.5 hours at 63~67 DEG C with smudge cells, after after 80~120 mesh filter screen coarse filtrations, the filtering of 270~325 mesh filter screen essences, obtains lentinan drink.The present invention solves problem in the prior art using Liquid Culture, has evaded the side effect of Lentinan, has utmostly played the useful effect of the various composition of mushroom.
Description
Technical field
The invention belongs to the preparation method technical fields of edible fungus fermented type functional food, and in particular to a kind of mushroom is more
The production method of sugar beverage.
Background technique
Mushroom nutritive value is very high, is people's important edible and medical fungus and flavouring, and a kind of natural function
Food.Mushroom contains more than ten kinds of amino acid, wherein having isoleucine, lysine, phenylalanine, methionine, threonine, valine
Deng 7 kinds of amino acid needed by human.In every hectogram dried thin mushroom containing 13 grams of protein, fat 1.8 grams, 54 grams of carbohydrate,
7.8 grams of crude fibre, 4.9 grams of coarse ash and multivitamin and mineral salt；124 milligrams of calcium, 415 milligrams of phosphorus, iron in ash content
25.3 grams；0.07 milligram of B1 (thiamine), 1.13 milligrams of B2 (riboflavin), 18.9 milli of B3 (nicotinic acid, niacin) in vitamin
Gram, 260 milligrams of provitamin D (ergosterol).Mushroom has strong inhibiting effect to cancer cell, to small white mouse sarcoma S-180
Inhibiting rate be 97.5%, be 80% to the inhibiting rate of ehrlich ascites tumor.Mushroom is applied not only to anti-curing cancers also to diabetes, lung
Tuberculosis, catarrhal jaundice, neuritis etc. play therapeutic effect, it may also be used for indigestion, constipation, weight-reducing etc..Mushroom also contains double
Chain ribonucleic acid can induce generation interferon, have antivirus action.
The main component of mushroom is polysaccharide and unsaturated fatty acid, also containing the wheat that can be largely changed into vitamin D
Angle sterol and fungisterol, lentinan are the effective active composition extracted from high quality mushroom fruiting body, molecular formula: (C6H10O5)
N, molecular weight: 40~800,000.The T cell activity that people Xiu Nei has immune function is adjusted in the lentinan extracted through hot water, can drop
The ability of low methyl cholanthrene induced tumor.Research shows that the active polysaccharide ingredient β of mushroom-(1 → 3)-D- glucan is different to inhibition
Source, homologous, even genetic tumour is all effective.And lentinan cure mainly cannot perform the operation or Recurrent Gastric Carcinoma, liver cancer,
Bladder cancer can alleviate symptom using lentinan, improve patient's immune function, correct disorder of tracelements.Lentinan can also
Promote T, B cell lymphopoiesis, improve the effects of NK cell activity, antiviral, liver protecting, be it is a kind of by improve from
Body immunity is current by improving autoimmunity to resist the disease to play the anticancer ancillary drug of immunoregulation effect
Think best treatment method.Specifically, its bioactivity includes
1. the anti-tumor activity of lentinan
Lentinan has antitumor action, it does not have the toxic side effect of chemotherapeutics.Lentinan lures after entering antibody
Artificial delivery is raw a kind of with immunocompetent cell factor, under the comprehensive function of these cell factors, body immune system enhancing,
Defence and lethal effect are risen to tumour cell.
Lentinan is played anti-by activating macrophage, the cell toxicant (ADDC) of enhancing antibody dependent cellular induction
Tumor promotion；In addition, lentinan can also make the blood vessel dilatation and bleeding of tumor locus, leads to tumour hemorrhagic necrosis and move back completely
Change.
2. the immunological regulation of lentinan
The immunoregulation effect of lentinan is the important foundation of its bioactivity.Lentinan is that typical T cell swashs
Agent living, promotes the generation of interleukins, moreover it is possible to promote the function of mononuclear macrophage, it is considered to be a kind of specifc immunity enhancing
Agent.Its immunization feature is that it can promote the generation of lymphocyte activating factor (LAF) (LAE), discharges various helper T lymphocytes
The factor enhances host's Peritoneal macrophage function, restores or stimulate the function of helper T lymphocyte.In addition, lentinan can also
Promote antibody tormation, inhibits macrophage release.
3. the antiviral activity of lentinan
There is research to think, mushroom contains a kind of double stranded RNA, human body desmacyte and white blood cell can be stimulated to discharge dry
Element is disturbed, and interferon has antivirus action.Shiitake mushroom hypha extract absorption herpesviral capable of inhibiting cell, to prevent and treat
Various diseases caused by herpes simplex virus, cytomegalovirus.A kind of substance is extracted from the shiitake mushroom hypha of culture, can be made
Because the T lymphocyte of AIDS viral infection is restored, stimulating expression of macrophage helps to create Antybody therapy AIDS, and safety
It is without side-effects.
There is scholar to find that sulphation lentinan has the activity of AIDS virus resisting (HIV), may interfere with retrovirus
And the absorption and intrusion of other viruses.Japanese scholars report, the one kind obtained from mushroom fruiting body have good antitumor work
The sulfated derivative of glucan can inhibit the activity of HIV.
4. lentinan anti-infectious function
It is reported that lentinan can improve macrophage function.Lentinan to Abelson virus, 12 type adenovirus and
Influenza infection has inhibiting effect, is the good drug that the various hepatitis for the treatment of are especially chronic migration-type hepatitis.
The current application of lentinan includes:
1. lentinan is in the application of field of medicaments
Lentinan treat gastric cancer, colon cancer, in terms of have good efficacy.It is fragrant as immune ancillary drug
Mushroom polysaccharide is mainly used to inhibit generation, development and the transfer of tumour, improves the sensibility of tumours of chemotherapeutic agents, improves patient's
Physical condition extends its service life.
Lentinan and chemotherapeutic agent use, and play the role of attenuation, synergy.The selection of chemotherapeutics killing tumor cell
Property it is poor, also there is lethal effect to normal cell, generate toxic side effect, cause chemotherapy that cannot carry out according to quantity on schedule；Due to changing
The underdosage for the treatment of, the drug resistance of Chang Yinqi tumour cell, becomes intractable cancer, affects the treatment.Perfume (or spice) is taken in chemotherapy process
Mushroom polysaccharide, can be enhanced the curative effect of chemotherapy, and mitigate the toxic effect of chemotherapy；Meanwhile in chemotherapy process under the leucocyte of patient
Incidence, gastrointestinal toxicity, hepatic disorder and the vomiting of drop are substantially reduced.This has absolutely proved lentinan and chemotherapy
And with and the immune function of patient's body can be enhanced with synergy, attenuation.
Lentinan cooperates other drugs to treat chronic hepatitis B, and the effect of turning out cloudy of hepatitis b virus marker can be improved,
Reduce the side effect of antiviral drugs.In addition, lentinan can be used for treating mycobacterium tuberculosis infection.
2. lentinan is in the application of field of health care food
Lentinan is a kind of special bioactive substance, is a kind of biological respinse reinforcing agent and regulator, it can increase
Strong humoral immunity and cellular immune function.It is immune that the Antiviral mechanism of lentinan may is that it improves infection cell
Power enhances the stability of cell membrane, inhibits cytopathy, promotes the functions such as cell repair.Meanwhile lentinan also have it is degeneration-resistant
Retroviral activity.Therefore, lentinan is a kind of health food of untapped anti influenza.
Clinically there are commonly lentinan pulvis and Lentinans at present, and there is active cell to be immunized, adjust
A variety of humoral indications, induction alpha-interferon generate, and adjust immune response reaction, induction leucocyte to tumor-infiltrated,
Lead to tumor locus blood vessel dilatation, bleeding, necrosis, prevent the combination of virus and host cell, improve SOD activity, inhibits MDA raw
At lipid peroxidation inhibition reduces cholesterol, adjusts glycometabolism, improves sugar tolerance, expands gastrointestinal tract generation satiety and mitigate food
The effects of being intended to, reducing blood glucose.
Clinic is often shared with Tegafur (FT207), adriamycin (ADR), mitomycin (MMC), and treatment cannot be performed the operation or be answered
The gastric cancer of hair.It can also be used for colorectal cancer, lung cancer, breast cancer, acute and chronic leukemia, chronic viral hepatitis type B to control
It treats.To the patients with advanced cancer of existing distant organ transfer, this product is shared in chemotherapy can improve the systemic conditions of patient, improve
Curative effect extends life cycle.
But accidental adverse reaction has:
1. shock: it is more rare, therefore close observation is answered after patient's medication.It is different to there is exception, chilly, the rhythm of the heart in mouth
Often, should be discontinued simultaneously appropriate processing in time immediately when the symptoms such as blood pressure decline, expiratory dyspnea.
2. skin: it is accidental fash, rubescent, it should be discontinued in time, necessity is handled.
3. respiratory system: close observation is answered in the narrow sense of accidental pressure in chest, throat.Administration speed should be slowed down when generation
4. digestive system: accidental Nausea and vomiting, loss of appetite.
5. nervous system: accidental headache, it is nose heave, dizzy.
6. blood: accidental red, leucocyte and decreased hemoglobin.
7. other: accidental fever, the symptoms such as perspiration, flush.
Lentinan product huge number, mainly has injection, capsule, tablet, pulvis etc., clinically commonly on the market
Have lentinan pulvis and a Lentinan, most products are extracted from mushroom fruiting body, heavy workload, low efficiency, at
It is this height, seriously polluted, expensive, and take Lentinan be found shock, fash, Nausea and vomiting, loss of appetite,
The adverse reactions such as dizziness.In addition, may is that production process technical difficulty is larger, wants to technical staff because strain degeneration is fast
Very high reason is sought, the product of sargassum fusiforme polysaccharide beverage that so far there are no (liquid beverage), and in the patent application for being related to lentinan
In, the method for liquid production lentinan is very few, and is only the test in laboratory, there is no the report of large-scale production
Road.Therefore, it is necessary to lentinus edodes health care food and preparation method thereof is further improved, provide it is more effective, safer, can be big
Measure the product of production.
Summary of the invention
It is an object of the invention to provide a kind of producer of lentinan drink in place of overcome the deficiencies in the prior art
Method solves problem in the prior art using Liquid Culture, has evaded the side effect of Lentinan, utmostly played
The useful effect of the various composition of mushroom.
The technical solution adopted by the present invention to solve the technical problems is:
A kind of production method of lentinan drink, mushroom strain are successively seeded in different types of rejuvenation culture medium and train
Rejuvenation is supported, is cultivated 18~22 days in each type of rejuvenation culture medium；The strain to grow fine is accessed in fluid nutrient medium, into
Row multistage amplification cultivation, every level-one 23~27 DEG C shake culture 5~7 days, every grade of inoculum concentration 10%~30%；Multistage amplification training
It supports obtained bacterial culture fluid and at 63~67 DEG C keeps the temperature 1.5~2.5 hours with smudge cells, it is thick through 80~120 mesh filter screens after
After filtering, the filtering of 270~325 mesh filter screen essences, lentinan drink is obtained；Wherein,
The rejuvenation culture medium is according to the mass fraction, comprising: corn flour or wheat flour or millet flour or buckwheat 28~32
Part, 18~22 parts of sucrose, 18~22 parts of wheat bran, 18~22 parts of rice bran, 2~4 parts of potassium dihydrogen phosphate, 2~4 parts of dipotassium hydrogen phosphate,
1~2 part of magnesium sulfate, 2~4 parts of yeast extract, 28~32 parts of agar；
The fluid nutrient medium is according to the mass fraction, comprising: and 28~32 parts of corn flour, 18~22 parts of sucrose, wheat bran 18~
22 parts, 18~22 parts of rice bran, 2~4 parts of potassium dihydrogen phosphate, 2~4 parts of dipotassium hydrogen phosphate, 1~2 part of magnesium sulfate, yeast extract 2~4
Part.
In one embodiment: the rejuvenation culture medium includes the following component based on formula rate: corn flour or wheat flour or
Millet flour or 30 grams of buckwheat, 20 grams of sucrose, 20 grams of wheat bran, 20 grams of rice bran, 3 grams of potassium dihydrogen phosphate, 3 grams of dipotassium hydrogen phosphate, sulphur
1.5 grams of sour magnesium, 3 grams of yeast extract, 30 grams of agar, 1000 milliliters of water.
In one embodiment: the fluid nutrient medium includes the following component based on formula rate: 30 grams of corn flour, sucrose 20
Gram, 20 grams of wheat bran, 20 grams of rice bran, 3 grams of potassium dihydrogen phosphate, 3 grams of dipotassium hydrogen phosphate, 1.5 grams of magnesium sulfate, 3 grams of yeast extract, water
1000 milliliters.
In one embodiment: the multistage amplification cultivation is 3~6 grades of amplifications.
In one embodiment: the multistage amplification cultivation method particularly includes: take out strain from rejuvenation culture medium and be inoculated into
In 45~55 milliliters of fluid nutrient medium, the product that 45~55 milliliters of liquid culture medium culture obtains be transferred to 240~260 milli
In the fluid nutrient medium risen, the obtained product of 240~260 milliliters of liquid culture medium culture be transferred to 480~520 milliliters of liquid
In body culture medium, the product that 480~520 milliliters of liquid culture medium culture obtains be transferred to 1400~1600 milliliters liquid training
It supports in base.
In one embodiment: after the filtering, honey is added and adjusts mouthfeel.
In one embodiment: the lentinan drink is sterilized, it is filling after, obtain finished product.
In one embodiment: the rejuvenation culture medium is sterilized 25~35 minutes using preceding at 120~126 DEG C.
In one embodiment: the fluid nutrient medium is sterilized 25~35 minutes using preceding at 120~126 DEG C.
The technical program compared with the background art, it has the following advantages:
A, the present invention carries out rejuvenation by multistage cultivate, and solves bacterial strain and is easy to degenerate and cause asking for product quality decline
Topic；
B, the present invention in liquid medium, uses natural cereal rice bran, wheat bran as culture medium and addition chemistry is replaced to close
At vitamin, improve the quality of product, and keep product safer；
C, the present invention carries out multistage amplification in shorter cultivation cycle, reduces production cost；
D, the present invention is extracted in lower temperature smudge cells, product is enabled largely to keep effective component
Bioactivity；
E, the present invention uses multistage filtering, not only reduces the difficulty of filtering, remains the effective component of product, and makes
Appearance and the mouthfeel for obtaining product are more preferable.
F, this method produces sargassum fusiforme polysaccharide beverage using Liquid Culture, remains the various effective components of mushroom such as polysaccharide, more
Peptide, quinones etc..The present invention enriches the kind of lentinan product.The beverage can not only replace the effect of pulvis and capsule, and
And since the product is pure natural, other additives are not added, not only avoids and above-mentioned takes Lentinan and pulvis institute
The adverse reaction of generation, and the other compositions such as polypeptide, quinones in mushroom than single lentinan ingredient to other types
Disease such as viral diseases can more play extensive treatment and preventive and therapeutic effect.Information through application feedback shows to drink the production
After product, autoimmunity is improved, the raising, sleep of leukocyte cell after appetite increase, good, full of vitality, the advantageous chemotherapy of defaecation
Improve and reduce even without analgesic and spirit quieting medicine, it is sick to preventing and treating that many cases drink patient feedback's sargassum fusiforme polysaccharide beverage
The disease of malicious class has good effect.
Detailed description of the invention
Present invention will be further explained below with reference to the attached drawings and examples.
Fig. 1 is one of the culture effect photo for adding the culture medium and remaining culture medium of wheat bran and rice bran, in figure from a left side to
The right side is respectively un-added control group, addition VB1 group, addition wheat bran group, addition wheat bran and rice bran group.
Fig. 2 be add the culture medium and remaining culture medium of wheat bran and rice bran culture effect photo two, in figure from a left side to
The right side is respectively un-added control group, addition VB1 group, addition wheat bran group, addition wheat bran and rice bran group.
Fig. 3 be add the culture medium and remaining culture medium of wheat bran and rice bran culture effect photo three, in figure from a left side to
The right side is respectively addition wheat bran and rice bran group, un-added control group, addition VB1 group, addition wheat bran group.
Fig. 4 be add the culture medium and remaining culture medium of wheat bran and rice bran culture effect photo four, in figure from a left side to
The right side is respectively un-added control group, addition VB1 group, addition rice bran group, addition wheat bran and rice bran group, addition wheat bran and rice bran
Group.
Specific embodiment
The contents of the present invention are illustrated below by embodiment:
A kind of production method of lentinan drink, takes mushroom strain, is successively seeded to different types of rejuvenation culture medium
Middle culture rejuvenation cultivates 18~22 days in each type of rejuvenation culture medium, makes rejuvenation of spawn；The bacterium that will be grown fine after rejuvenation
In kind of access fluid nutrient medium, carry out multistage amplification cultivation, every level-one 25 DEG C shake culture 5~7 days, every grade of inoculum concentration 10%
~30%；The bacterial culture fluid that multistage amplification cultivation obtains keeps the temperature 2 hours at 65 DEG C with smudge cells, keeps intracellular mushroom more
The substances such as sugar, polypeptide, protein, enzyme, quinones are released, after after 100 mesh filter screen coarse filtrations, the filtering of 300 mesh filter screen essences,
A small amount of honey adjustment mouthfeel is added as needed, is filled to after sterilizing in 100 milliliters of bottle, obtain lentinan drink at
Product.
Wherein,
The formula of rejuvenation culture medium are as follows: corn flour or 30 grams of wheat flour or millet flour or buckwheat, 20 grams of sucrose, wheat bran 20
Gram, 20 grams of rice bran, 3 grams of potassium dihydrogen phosphate, 3 grams of dipotassium hydrogen phosphate, 1.5 grams of magnesium sulfate, 3 grams of yeast extract, 30 grams of agar, add water
It 1000 milliliters, is uniformly mixed, cooling solidification after heating for dissolving, 121 DEG C sterilize 30 minutes.
The formula of fluid nutrient medium are as follows: 30 grams of corn flour, 20 grams of sucrose, 20 grams of wheat bran, 20 grams of rice bran, potassium dihydrogen phosphate 3
Gram, 3 grams of dipotassium hydrogen phosphate, 1.5 grams of magnesium sulfate, 3 grams of yeast extract, add 1000 milliliters of water, be uniformly mixed, 121 DEG C sterilize 30 points
Clock.
The emphasis of method of the invention is as follows:
A, rejuvenation strain is used alternatingly by culture medium starch component millet, corn, buckwheat, wheat etc., solves bacterium
The problem of strain is degenerated fastly, and product quality declines；Lenlinus edodes are degenerated quickly during the cultivation process, have severely impacted the matter of product
Amount, it is difficult to continuous production.It is used alternatingly by a variety of culture mediums, solves strain degeneration with the method for rejuvenation bacterial strain and cause product matter
The problem of amount decline, makes every time used to be all to have stronger active bacterial strain, to guarantee the quality of product.
Strain long term storage and long-time service and tube number are excessive, can all vigor be caused to decline, it is therefore necessary to carry out
Rejuvenation of spawn work, the method for rejuvenation have: isolating and purifying, activate transplanting, replacement culture medium, the culture medium for converting different formulations can
To enhance new viability, promote breeding rejuvenation.What strain of the invention was bought from mushroom grower from " Sanming-City Inst of Funguses "
Lenlinus edodes are accessed different (corn, buckwheat, millet, wheat) solid rejuvenation and trained by bacterial strain, the strain for taking growing way good from mushroom grower
Support and cultivated in base, every kind culture medium culture about 20 days or so, screen the bacterial strain to grow fine and carry out conservation and production, then by growing way
Multistage amplification cultivation is carried out in the fluid nutrient medium that good strain access sterilizes 30 minutes through 121 DEG C.Various types of rejuvenation trainings
Support the unlimited using sequence and number of base.For example, mushroom strain is first cultivated in corn rejuvenation culture medium among the present embodiment
It 20 days, chooses in the strain immigration wheat rejuvenation culture medium to grow fine and cultivates 20 days, then choose the strain to grow fine and move into
It is cultivated 20 days in millet rejuvenation culture medium, then chooses in the strain immigration buckwheat rejuvenation culture medium to grow fine and cultivate 20 days, it is real
The purpose of existing rejuvenation.
B, the formula of fluid nutrient medium of the invention are as follows: 30 grams of corn flour, 20 grams of sucrose, 20 grams of wheat bran, 20 grams of rice bran, phosphorus
3 grams of acid dihydride potassium, 3 grams of dipotassium hydrogen phosphate, 1.5 grams of magnesium sulfate, 3 grams of yeast extract add 1000 milliliters of water.The fluid nutrient medium
Formula is to pass through structure adjusting starch, sugar, potassium magnesium ion, vitamin and wheat in the prior art on the basis of solid medium
Obtained by the dosage and combination of the ingredients such as bran, rice bran.(recipe determination scheme such as subordinate list 1, subordinate list 2)
In test, when the corn flour in formula is more than 30 grams, maize powder medium is not finished, and is less than 30 grams of jade
Edible mushroom cenobium is less in the culture liquid of rice flour, requirement of the different incubation times to culture medium be also it is different, this
Selected in the formula of invention every liter with 30 grams of corn flour.
Subordinate list 1 is the test to dosages such as sucrose, glucose, wheat bran, potassium phosphates, the results showed that uses sucrose and glucose
The result difference of the edible mushroom of culture is little, and cost is relatively low with sucrose；Wheat bran is higher using every liter of 20 grams of utilization rates；And phosphorus
Acid dihydride potassium has a certain impact with amount and size of the dipotassium hydrogen phosphate dosage to thallus.
In order to solve the influence of potassium dihydrogen phosphate, dipotassium hydrogen phosphate to edible mushroom cenobium, the present invention has made further subordinate list 2
The size of test, experimental result discovery dipotassium hydrogen phosphate dosage will affect the growth of edible mushroom cenobium, the edible mushroom when dosage is big
Cenobium amount is few, cenobium becomes larger, therefore in production, when needing biggish edible mushroom cenobium when reproductive order of generation, can pass through
The dosage of potassium is adjusted to adjust the size of edible mushroom cenobium.Conversely, needing that phosphoric acid hydrogen can be reduced when lesser edible mushroom cenobium
The dosage of dipotassium.And determine that the dosage of potassium dihydrogen phosphate and dipotassium hydrogen phosphate is 3 grams every liter by the test.
Subordinate list 1: one of screening of medium formula
Subordinate list 2: the comparison of potassium dihydrogen phosphate, dipotassium hydrogen phosphate, wheat bran dosage
Wheat bran and rice bran are added in the fluid nutrient medium that the present invention uses, and improve the quality of product；The producer is training
When supporting mushroom strain, majority uses PDA culture medium (200 grams of potato, 20 grams of glucose, 20 grams of agar, 1000 milliliters of water)；
PSA culture medium (200 grams of potato, 20 grams of sucrose, 20 grams of agar, 1000 milliliters of water)；CPDA culture medium (200 grams of potato, Portugal
Grape sugar 20 grams, 20 grams of agar, 2 grams of potassium dihydrogen phosphate, 0.5 gram of magnesium sulfate, 1000 milliliters of water) etc. carry out mushroom parent species culture
(" quoted from the practical new technology of cultivating champignon " Zhang Baojun writes), and fluid nutrient medium is that above formula does not add agar.And it is old
Scholar's fine jade writes mushroom fluid nutrient medium in " mushroom production technology pandect ", and there are five types of be formulated i.e.: 1, wheat bran 5%, glucose 2%, sulphur
Sour ammonium 0.1%, magnesium sulfate 0.04%, zinc sulfate 0.02%, boric acid 0.01%, land plaster 1%, 1 milliliter of vitamin B12, agar
0.05%, pH is natural；2, potato 20%, glucose 2%, ammonium sulfate 0.2%, potassium dihydrogen phosphate 0.1%, magnesium sulfate
0.05%, 10 milligrams/1 liter of vitamin B1, agar 0.05%, pH are natural；3, soluble starch 7%~9%, glucose 1%,
Corn pulp 1.5%~2%, potassium dihydrogen phosphate 0.1%, 9 mg/litre of zinc sulfate；4, citric acid fermentation waste water (containing sugar 1.5%)
90%, wheat bran leachate 8%, sweet potato powder 1%, pH6.5；5, sucrose 3%, potassium dihydrogen phosphate 0.1%, magnesium sulfate 0.1%, wheat bran
Leachate 5%, corn pulp 0.3%, pH6.5.Some mushroom growers have the ingredient of addition rice bran and wheat bran in solid medium, due to behaviour
Make troublesome, easy to pollute and will affect and drink mouthfeel, no added rice bran ingredient in the formula of fluid nutrient medium, the present invention, which uses for reference, to be consolidated
The method of body culture overcomes its disadvantage, increases the substances such as wheat bran and rice bran and replaces chemically synthesized vitamin, through test strain energy
It grows well and product is more safe and environment-friendly.Human needs are made to be difficult to wheat bran and rice bran edible and absorb again, by edible
After bacterium effectively absorbs conversion, resupplies the mankind and eat (seeing attached list 3 and attached drawing).
Attachment 3: one of addition wheat bran, the multiple comparative experiments of rice bran
Note: it can be seen in the drawings that culture medium other compositions are identical, cultivation results addition wheat bran, rice bran with add VB1
Bacterial strain growing way is better than the control that do not add, and only the bacterial strain growing way of plus wheat bran is slightly worse than the culture solution for adding rice bran liquid.
C, multistage amplification is carried out in a relatively short period of time, reduces production cost；Since production link needs to carry out strain
Multistage amplification, and every grade of growth cycle of strain needs the regular hour, every batch of product is from fluid nutrient medium is inoculated into as production
Product need to be more than the bimestrial time, cause the production time of product long, at high cost.The present invention explores while multistage progress
The method of the amplification cultivation of several ranks takes out the Liquid Culture that strain is inoculated into 50 milliliters that is, from the solid medium of rejuvenation
In base, the liquid spawns of 50 milliliters of cultures be transferred in 250 milliliters of fluid nutrient medium, 250 milliliters of liquid spawn switching 500
In the fluid nutrient medium of milliliter, 500 milliliters of liquid spawn is transferred in 1500 milliliters of fluid nutrient medium.Every level-one inoculum concentration
About 10%~30% (after the strain collection of products that i.e. every level-one culture obtains, takes 10%~30% (mass percent) to be inoculated with
Enter next stage culture medium and carry out next stage culture), every level-one culture is shake culture 7 days in 25 DEG C of shaking tables.Pass through several cultures
Case or an incubator carry out level Four culture simultaneously, guarantee the bioactivity of bacterial strain, shorten the production time, reduce and be produced into
This.
D, it in 65 DEG C of heat preservation a few hours smudge cells, is extracted, product is enabled largely to keep its effective component
Bioactivity；Most producers, which carry out smudge cells using high temperature mode, makes it discharge intracellular substance, although convenient
High temperature will cause the effective component such as enzyme in mushroom culture solution and lose or reduce activity, polysaccharide, polypeptide, protein degradation, destroy
The effective component of mushroom causes product that can not play its best effect.The present invention carried out in lower temperature clasmatosis,
Extraction largely keeps the bioactivity of the effective component of liquid Lenlinus edodes.It is past in the prior art for product appearance consideration
It is adjusted to alkalinity toward by pH value, prevents the generation of sediment.Lenlinus edodes can be grown between pH3~7, but have a preference for acyclic acidic
Border.Present invention discover that lentinan drink effect in slightly acid environment is more preferable, although product has sediment generation, sense organ
It is poor, but the effect for being conducive to effective component in product plays, and there is no need to again as in the prior art adjusting pH value
For alkalinity.
E, make the mouthfeel of product more preferable using multistage filtering；Due to more by broken liquid mushroom cell debris, glutinous
Degree is big, and difficulty in filtration is larger.It is a discovery of the invention that carrying out the strainer coarse filtration of 100 mesh and the strainer of 300 mesh to broken liquid
Essence filtering, not only reduces the difficulty of filtering, remains the effective component of product and make product appearance and mouthfeel more preferable.
Due to the pollution of living environment, the patient for suffering from cancer is more and more, and modern medicine finds just to have a cancer in every six seconds
Disease patient generates.The present invention brings glad tidings to cancer patient, and it is cheaper than lentinan pulvis to be not only price, and its effectively at
Divide higher.There are good economic benefit and social benefit.Inventions have been the production of the small lot of many years and tests, take
Good effect, set about groping for the construction for the production line being mass produced and condition of expanding production, can be used for industry
Metaplasia produces.
By the test more than 7 years, the personnel for drinking this product have liver cancer, lung cancer, breast cancer, colon cancer, bladder cancer, stomach
The cancer patients such as cancer, thyroid cancer；There are baby, child, old man to suffer from influenza, parotitis, hand-foot-and-mouth disease and senile asthma, allergy
Etc. related symptoms have apparent relaxation effect and adverse reaction do not occur.
1 patient Lin Xiansheng of case: nineteen fifty-seven birth, in September, 2009 are diagnosed as Primary Hepatic in Concord Hospital, Fujian Province
Cancer starts to drink sargassum fusiforme polysaccharide beverage, so far from June, 2012, accomplishes that daily 2 bottles of mushrooms are more substantially during treating with rehabilitation
Sugar beverage is felt good.With it is previous relatively less fatiguability, catch a cold, treat less after constitution recovery fastly.In recent years, through more
Secondary check, stable disease live normal, activity freely.Patient's readme sargassum fusiforme polysaccharide beverage is for enhancing body immunity, stabilization
The state of an illness restorative truly has help.
2 patient Mrs Zhou of case: being born, be diagnosed as left lung squamous cancer in Fujian Cancer Hospital in June, 2012 for 1958,
The radiotherapy of chemotherapy and a course for the treatment of through four courses for the treatment of, the state of an illness are controlled.2012 6 during treatment herein and rehabilitation in the future
The moon so far, adhere to drinking 2 bottles of sargassum fusiforme polysaccharide beverages daily, drinks descendant and do not tire out, have spirit, be not easy to catch a cold.The state of an illness for many years
All-the-time stable, in order, quality of life are good.Patient's readme drinks sargassum fusiforme polysaccharide beverage to raising body immunity, stable disease
Feelings, improvement physical condition are really helpful.
3 patient Wang Nvshi of case: nineteen twenty-seven birth, in December, 2016 see a doctor because of hematochezia and are diagnosed in Zhongshan Hospital, Xiamen City
To break up gland cancer in colon ascendens.Older because considering, refusal carries out operative treatment, conservative treatment is selected, from December, 2016
It drinks 2 bottles of sargassum fusiforme polysaccharide beverages daily so far within 25th, feels good.When just starting to drink, stool is relatively previous smooth daily, and arranges
Just timing, without adverse side effect.It is lived still as not before the onset now, good appetite does not have found hematochezia, life action certainly
Such as.
It is born within 4 patient of case Zheng Nvshi: 1966 years, the end of the year 2015 were found thyroid tumors, 2 months 2016 surgery Pathologies
Analysis be papillary carcinoma, after operation drink sargassum fusiforme polysaccharide beverage.Postoperative feeling people does not have to drink 2 bottles when strength, restores
1 bottle is drunk when to preoperative state daily, there is interval couple of days in centre sometimes.Patient's readme take after feel people it is full of physical strength,
Resistance enhancing drinks more than 2 years and does not all catch a cold, and doctor's requirement takes left thyroid gland sodium piece and reduces to 50 from daily 200 microgram
Microgram, body indices are all in control range.
5 patient Miss Wu of case: being born for 1963, and 2013 because of mammary cancer surgery, Bone of Breast Cancer transfer in 2016, to south
Zong Yuan tumour two section in capital military region Foochow receives chemotherapeutic treatment.Patient's readme has carried out chemotherapy three times at present, and it is more continuously to take mushroom
After sugared oral solution, leucocyte index is always held at normal value, and red blood cell is also risen on the basis of the original.Do not connect such as
It is continuous to use shiitake fungus polyoses oral liquid, then feel that physical strength is decreased obviously, be easy fatigue, poor, poor appetite of sleeping, particularly blood pressure down to
86/55。
6 patient Ms Zhang of case: being born, be diagnosed as breast cancer in April, 2018 for 1949, starts to drink 2 bottles daily from June
Sargassum fusiforme polysaccharide beverage is felt good, and life so far, activity are freely.
7 patient Mr. Wang of case: age one's mid-60s suffer from 25 centimeters of liver cancer, and daily 2 bottles, the conscious disease of patient's readme
Shape continues to be improved or mitigate earlier above, wherein the most it is apparent that hepatic region not bitterly, other symptoms also have it is apparent improve and
Mitigate, especially sleep quality is obviously improved.Sargassum fusiforme polysaccharide beverage can be reduced pain, improve the quality of living, and patient is before taking
It can only lie on a bed, after drinking sargassum fusiforme polysaccharide beverage, reduce or stopped and take morphine and hypnotic, can get up walking,
Achieve the purpose that deathbed care.
8 patient Li Nvshi of case: readme, which takes to need weekly before sargassum fusiforme polysaccharide beverage to play two needles, brightens needle, takes lentinan
It is not required to beat again after drink to brighten needle.
9 pet Sa Moye fallopian tubal inflammation of case is had an operation, preoperative white blood cell 3.6 ten thousand, postoperative to drink 3 days lentinan drinks
Product, daily 100 milliliters, third day checks that white blood cell rises to 4.6 ten thousand, and it is that white blood cell is restored to 6 that 3 days inspection results are drunk in stopping
Thousand.
From the point of view of the effect of about 50 or so on probation cancer patients and 80 multidigit other patients, most of user recognizes
To there is different degrees of effect.It is bright that effect is prevented and treated to the flu of the virus types such as child's stomatopod hand disease, parotitis, influenza
It is aobvious；There is apparent constitutional effect to the patient, asthmatics, elderly and infirm of bronchitis of old people；To cancer
Increase white blood cell after people's chemicotherapy, the immunity for having enhancing itself, improves sleep quality, increases the apparent effects such as appetite.
The above is only the preferred embodiment of the present invention, the range implemented of the present invention that therefore, it cannot be limited according to, i.e., according to
Equivalent changes and modifications made by the invention patent range and description, should still be within the scope of the present invention.
Claims (9)
1. a kind of production method of lentinan drink, it is characterised in that: mushroom strain is successively seeded to different types of rejuvenation
Rejuvenation is cultivated in culture medium, is cultivated 18~22 days in each type of rejuvenation culture medium；The strain to grow fine is accessed into liquid
In culture medium, carry out multistage amplification cultivation, every level-one 23~27 DEG C shake culture 5~7 days, every grade of inoculum concentration 10%~
30%；The bacterial culture fluid that multistage amplification cultivation obtains keeps the temperature 1.5~2.5 hours at 63~67 DEG C with smudge cells, passes through after
After 80~120 mesh filter screen coarse filtrations, the filtering of 270~325 mesh filter screen essences, lentinan drink is obtained；Wherein,
The rejuvenation culture medium is according to the mass fraction, comprising: corn flour or 28~32 parts of wheat flour or millet flour or buckwheat, sugarcane
Sugared 18~22 parts, 18~22 parts of wheat bran, 18~22 parts of rice bran, 2~4 parts of potassium dihydrogen phosphate, 2~4 parts of dipotassium hydrogen phosphate, magnesium sulfate
1~2 part, 2~4 parts of yeast extract, 28~32 parts of agar；
The fluid nutrient medium is according to the mass fraction, comprising: 28~32 parts of corn flour, 18~22 parts of sucrose, 18~22 parts of wheat bran,
18~22 parts of rice bran, 2~4 parts of potassium dihydrogen phosphate, 2~4 parts of dipotassium hydrogen phosphate, 1~2 part of magnesium sulfate, 2~4 parts of yeast extract.
2. the production method of lentinan drink according to claim 1, it is characterised in that: the rejuvenation culture medium includes
Following component based on formula rate: corn flour or 30 grams of wheat flour or millet flour or buckwheat, 20 grams of sucrose, 20 grams of wheat bran,
20 grams of rice bran, 3 grams of potassium dihydrogen phosphate, 3 grams of dipotassium hydrogen phosphate, 1.5 grams of magnesium sulfate, 3 grams of yeast extract, 30 grams of agar, water 1000
Milliliter.
3. the production method of lentinan drink according to claim 1, it is characterised in that: the fluid nutrient medium includes
Following component based on formula rate: 30 grams of corn flour, 20 grams of sucrose, 20 grams of wheat bran, 20 grams of rice bran, 3 grams of potassium dihydrogen phosphate, phosphorus
3 grams of sour hydrogen dipotassium, 1.5 grams of magnesium sulfate, 3 grams of yeast extract, 1000 milliliters of water.
4. the production method of lentinan drink according to claim 1, it is characterised in that: it is described multistage amplification cultivation be
3~6 grades of amplifications.
5. the production method of lentinan drink according to claim 1, it is characterised in that: the multistage amplification cultivation
Method particularly includes: from the fluid nutrient medium that taking-up strain is inoculated into 45~55 milliliters in rejuvenation culture medium, this 45~55 milliliters
The product that fluid nutrient medium culture obtains is transferred in 240~260 milliliters of fluid nutrient medium, 240~260 milliliters of liquid is trained
The product that feeding base culture obtains is transferred in 480~520 milliliters of fluid nutrient medium, 480~520 milliliters of liquid culture medium is trained
Feeding obtained product is transferred in 1400~1600 milliliters of fluid nutrient medium.
6. the production method of lentinan drink according to claim 1, it is characterised in that: after the filtering, bee is added
Honey adjustment mouthfeel.
7. the production method of lentinan drink according to claim 1, it is characterised in that: the lentinan drink warp
After sterilizing, being filling, finished product is obtained.
8. the production method of lentinan drink according to claim 1, it is characterised in that: the rejuvenation culture medium makes
It is sterilized 25~35 minutes with preceding at 120~126 DEG C.
9. the production method of lentinan drink according to claim 1, it is characterised in that: the fluid nutrient medium makes
It is sterilized 25~35 minutes with preceding at 120~126 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910293617.XA CN109965166A (en) | 2019-04-12 | 2019-04-12 | A kind of production method of lentinan drink |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910293617.XA CN109965166A (en) | 2019-04-12 | 2019-04-12 | A kind of production method of lentinan drink |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109965166A true CN109965166A (en) | 2019-07-05 |
Family
ID=67084473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910293617.XA Pending CN109965166A (en) | 2019-04-12 | 2019-04-12 | A kind of production method of lentinan drink |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109965166A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112602663A (en) * | 2020-11-25 | 2021-04-06 | 云南酱香农业科技开发有限公司 | Disease prevention method in ecological pig breeding |
| CN116018144A (en) * | 2020-06-15 | 2023-04-25 | 玛希敦大学 | An antiviral pharmaceutical composition containing therapeutic agent derived from Astraeus Asiaticus |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078872A (en) * | 1993-05-20 | 1993-12-01 | 田子成 | Health drink prepared by mushroom double bacteria liquid fermentation method |
| CN104856150A (en) * | 2015-04-26 | 2015-08-26 | 哈尔滨伟平科技开发有限公司 | Manufacturing method of lentinan health-care beverage |
| CN108967038A (en) * | 2018-08-28 | 2018-12-11 | 铜陵盛牛菌业有限责任公司 | A kind of method of liquid strain cultivation mushroom |
-
2019
- 2019-04-12 CN CN201910293617.XA patent/CN109965166A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078872A (en) * | 1993-05-20 | 1993-12-01 | 田子成 | Health drink prepared by mushroom double bacteria liquid fermentation method |
| CN104856150A (en) * | 2015-04-26 | 2015-08-26 | 哈尔滨伟平科技开发有限公司 | Manufacturing method of lentinan health-care beverage |
| CN108967038A (en) * | 2018-08-28 | 2018-12-11 | 铜陵盛牛菌业有限责任公司 | A kind of method of liquid strain cultivation mushroom |
Non-Patent Citations (5)
| Title |
|---|
| 崔颂英等: "食用菌母种制作技术的几点改进", 《食用菌》 * |
| 张宝军: "《香菇栽培实用新技术》", 31 August 2017, 金盾出版社 * |
| 曾虹燕等: "《生物化学实验》", 31 October 2014, 湘潭大学出版社 * |
| 朱研静等: "香菇保健饮料的研制", 《食用菌》 * |
| 魏银初等: "《香菇栽培实操技术图解》", 30 November 2014, 中原农民出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116018144A (en) * | 2020-06-15 | 2023-04-25 | 玛希敦大学 | An antiviral pharmaceutical composition containing therapeutic agent derived from Astraeus Asiaticus |
| CN112602663A (en) * | 2020-11-25 | 2021-04-06 | 云南酱香农业科技开发有限公司 | Disease prevention method in ecological pig breeding |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN104829738B (en) | Application of sargassum graminifolium polysaccharide extract in improvement of intestinal flora and prevention and treatment of diabetes | |
| CN104946713B (en) | A kind of hypoglycemic peptide preparation method and applications based on sea cucumber albumen | |
| CN105658227B (en) | Composition for preventing and treating cancer-induced fatigue containing processed ginseng powder or processed ginseng extract with increased ginsenoside content | |
| CN101278730B (en) | Preparation of ganoderma lucidum rhodiola rosea oral liquid | |
| CN102160664A (en) | Nutritious drink for children | |
| CN104304577A (en) | Biological beverage with camellia chrysantha as carrier and preparation method thereof | |
| CN103190483A (en) | Children growth promotion milk tea | |
| CN109820905A (en) | A kind of pharmaceutical composition and its application for treating insomnia | |
| CN109965166A (en) | A kind of production method of lentinan drink | |
| CN106616947A (en) | Cordyceps militaris composition | |
| CN102090563A (en) | Relaxing and sleeping health-care food and preparation method thereof | |
| CN103829340B (en) | A kind of drinks and preparation method thereof | |
| CN104388236A (en) | Grape wine as well as preparation method and application thereof | |
| CN1602758A (en) | Nutritious liquor (drink) for relieving the effect of alcohol, alcohol relieving capsule production method | |
| CN102379391B (en) | Preparation of health food of pine pollen, glucan and natto | |
| CN107007646A (en) | A kind of nutrition compound of assisting in preventing and treating cancer | |
| CN100490829C (en) | Selenium-rich hedgehog fungus extract preparation for treating colitis, gastritis and stomach cancer and its preparing process | |
| CN105106577A (en) | Rose-flower-containing traditional Chinese medicine composition for treating diabetes | |
| CN104489472A (en) | Food for treating dyspepsia and diarrhea | |
| CN100544736C (en) | A kind of pharmaceutical composition of enhancing immunity and preparation method | |
| JPH08205819A (en) | Beverage for health | |
| CN101676401B (en) | Scorpion extract | |
| CN101642476A (en) | Production method of organic selenium ganoderma lucidum spore powder | |
| CN106387363A (en) | Iodine-enriched selenium-enriched chromium-enriched strengthening agent for eggs, as well as preparation method and use method of iodine-enriched selenium-enriched chromium-enriched strengthening agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190705 |
|
| RJ01 | Rejection of invention patent application after publication |